Format

Send to

Choose Destination
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Aug;112(2):195-202. doi: 10.1016/j.tripleo.2011.02.037. Epub 2011 May 31.

Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.

Author information

1
Dental Oncology Unit, Clinic of Hospital Dentistry, School of Dentistry, University of Athens, Athens, Greece. nicolatou.galitis@lycos.com

Abstract

OBJECTIVES:

The objectives of this study were to define the incidence, pain, and healing in cancer patients treated with intravenous bisphosphonates.

STUDY DESIGN:

The study included long-term follow-up of 99 bisphosphonate-using patients (group A) and conservative treatment of 67 patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ, group B) using 3 antibiotic schemes and oral hygiene.

RESULTS:

The frequency of zoledronic acid single-agent use was 85.9% and 69.8% in group A and B, respectively. Median follow-up was 13 months (group A) and 16 months (group B). Two patients in group A developed BRONJ (2%). Of those with BRONJ in group B who completed follow-up, healing occurred in 14.9% (7/47) and pain subsided in 80.9% (38/47). Healing was significant in patients who received pamidronate followed by zoledronic acid (P = .023) and with BRONJ stages 0 and stage I (P = .003).

CONCLUSIONS:

This case series suggests that oral hygiene and conservative antibiotic therapy play a role in healing and pain alleviation in BRONJ. Oral hygiene and follow-up may decrease incidence of BRONJ.

PMID:
21622014
DOI:
10.1016/j.tripleo.2011.02.037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center